

# **Bucci Laser Vision**

8/21/17

158 Wilkes-Barre Township Blvd.  
Wilkes-Barre, Pa., 18702  
1-877-DR-BUCCI  
www.BucciVision.com

## **PRESS RELEASE**

**Wilkes-Barre /Scranton Pennsylvania -**

**A first of its kind, new refractory Glaucoma treatment was performed by leading ophthalmologist Frank A. Bucci, Jr. MD., on Wednesday August 16, 2017.**

**The XEN gel stent, recently approved by the Food and Drug Administration is inserted during a microscopic surgical procedure, under light sedation and the eye surface is also numbed . The XEN gel stent is the size of an eye lash, its inserted through the wall of the eye, guiding excess fluid to exit the eyeball. If left untreated, refractory Glaucoma causes the pressure of eye to build creating progressive visual loss.**

**Patients who suffer from this disease often are unaware of the damage being caused until it is too late. Wednesday the first patient in Northeast Pennsylvania received this treatment performed by Dr. Bucci, founder of the Bucci Laser Vision Institute.**

**A prolific clinical trial researcher, Frank A. Bucci, Jr., MD participated in the FDA clinical trials which lead to its approval last fall. Prior to this medical advancement, conventional surgery would require an external incision, as well as an internal hole in the eye, which causes bleeding that requires it to be cauterized, and sutures. Pressures can go too low or remain too high. There is often inflammation and recovery time can take weeks.**

**In summary, *Allergan's* minimally invasive *Xen gel stent* has shown it can lower intraocular pressure and reduce topical medication/drops use without the inherent risk of traditional drainage surgery.**

**For more information or to schedule an evaluation contact Bucci Laser Vision at (570) 825-5949. Or visit <https://www.xengelstent.com>**